Atherogenic lipid profile and cardiovascular risk factors in HIV-infected patients (Nétar Study)

Int J STD AIDS. 2005 Oct;16(10):677-80. doi: 10.1258/095646205774357398.

Abstract

We undertook a transverse study of 603 HIV outpatients to determine their atherogenic lipid profile (ALP) and cardiovascular risk (CVR) factors. CVR was estimated from the Framingham score. ALP was defined as a total cholesterol to high density lipoprotein (HDL)-cholesterol ratio > or =5 plus triglycerides > or =150 mg/dL and a CVR >10% at 10 years was considered high. The most frequent CVR factor was smoking. ALP was diagnosed in 26.9% and was related to sex (odds ratio [OR] 2.6; 95% confidence interval [CI], 1.3-5.0; P = 0.0047), protease inhibitor use (OR 3.8; 95% CI, 1.8-7.8; P = 0.0002) and sexual HIV risk (OR 2.4; 95% CI, 1.4-4.0; P = 0.0004). The mean 10-year CVR was 6.2%, was high in 20.4% and was related to sexual HIV-risk (OR 3.8; 95% CI, 2.1-6.8; P < 0.00001) and nadir cell differentiation factor (CD4) (OR 1.0; 95% CI, 1.0-1.003; P = 0.0026). Although the current CVR of our patients is not high, the contribution to the lipid profile of highly active antiretroviral therapy (HAART)-associated factors and the high prevalence of some risk factors may lead to an increased future CVR.

MeSH terms

  • Adult
  • Antiretroviral Therapy, Highly Active / adverse effects*
  • Cardiovascular Diseases / complications
  • Cardiovascular Diseases / etiology*
  • Cholesterol / blood
  • Cholesterol, HDL / blood
  • Cholesterol, LDL / blood
  • Female
  • HIV Infections / blood
  • HIV Infections / complications*
  • HIV-1*
  • Humans
  • Lipids / blood*
  • Male
  • Middle Aged
  • Risk Factors
  • Triglycerides / blood

Substances

  • Cholesterol, HDL
  • Cholesterol, LDL
  • Lipids
  • Triglycerides
  • Cholesterol